Page last updated: 2024-11-02
pargyline and ADDH
pargyline has been researched along with ADDH in 2 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Wender, PH | 2 |
| Wood, DR | 2 |
| Reimherr, FW | 2 |
| Ward, M | 1 |
Trials
1 trial available for pargyline and ADDH
| Article | Year |
|---|---|
An open trial of pargyline in the treatment of attention deficit disorder, residual type.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Clinical Trials as Topic; Female; Humans; Male | 1983 |
Other Studies
1 other study available for pargyline and ADDH
| Article | Year |
|---|---|
Pharmacological treatment of attention deficit disorder, residual type (ADD,RT, "minimal brain dysfunction," "hyperactivity") in adults.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Humans; Methylphenidate; Pargyline; Pemoline; | 1985 |